Apo AI Nanoparticles Delivered Post Myocardial Infarction Moderate Inflammation
Adele L Richart, Medini Reddy, Mina Khalaji, Alaina L Natoli, Sarah E Heywood, Andrew L Siebel, Graeme L Lancaster, Andrew J Murphy, Andrew L Carey, Brian G Drew, Svetlana A Didichenko, Alexei V Navdaev, Bronwyn A Kingwell
Circulation Research | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020
RATIONALE: Decades of research have examined immune-modulatory strategies to protect the heart after an acute myocardial infarction and prevent progression to heart failure but have failed to translate to clinical benefit. OBJECTIVE: To determine anti-inflammatory actions of n-apo AI (Apo AI nanoparticles) that contribute to cardiac tissue recovery after myocardial infarction. METHODS AND RESULTS: Using a preclinical mouse model of myocardial infarction, we demonstrate that a single intravenous bolus of n-apo AI (CSL111, 80 mg/kg) delivered immediately after reperfusion reduced the systemic and cardiac inflammatory response. N-apo AI treatment lowered the number of circulating leukocytes by ..View full abstract
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Awarded by CSL Ltd
This work was supported by the National Health and Medical Research Council (NHMRC) of Australia (APP103652, B. A. Kingwell; 1059454 B.A. Kingwell); the Operational Infrastructure Support Scheme of the Victorian State Government. CSL Ltd provided partial financial support as well as the n-apo AI (Apo AI nanoparticles; CSL111) to the Baker Institute (B.A. Kingwell and A.L. Richart as named investigators) under a nonrestrictive Materials Transfer Agreement but had no role in either development of study design, data acquisition, or interpretation of data.